Nearly two years after moving his venture Insilico Medicine from the US to Hong Kong, Alex Zhavoronkov has grown more convinced of the view that the future of the world’s pharmaceutical industry lies in mainland China – especially with what he has observed in recent months – a trend of “much more aggressive” dealmaking efforts in the region.
End the Year with a Deal You Can’t Miss!
Subscribe now and save 40% on our premium subscription.
Enjoy unlimited access for a full year at just $199 (usual price $339).
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Offer valid for a limited time – don’t wait to unlock the insights that drive deal-making in Asia!
Subscribe nowAlready a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
